Nuformix Share Discussion Threads

[carlisle44] 22/3/2021 10:10

George 'remains protected to 2019' means out of protectrion now.

Did you misquote the date?

[soupdragon55] 22/3/2021 10:03

George, EMEND is out of patents and last year sales were around $100m

[georgeo1] 22/3/2021 09:47

https://www.google.com/amp/s/wap.business-standard.com/article-amp/international/glenmark-gets-usfda-nod-for-aprepitant-capsules-cancer-patients-to-benefit-117101600185_1.htmlHere is a generic product of Mercks Emend and is like of NXP001 Sales could be exceptional.

[georgeo1] 22/3/2021 09:33

MERCK equivalent to NXP001. Emend has been a solid product for Merck & Co, with sales last year rising 9% to reach $553m, but is approaching the end of its patent life. The US patent for the oral formulation expires this year, but the injectable remains protected until 2019, according to Merck.This back in 2015. Could be good news for nuformix and oxilio.

[georgeo1] 22/3/2021 09:20

From previous regards to NXP001. In oncology, Nuformix has granted Oxilio a six-month option over NXP001, which the latter will develop as a cancer treatment.If the option is triggered, Nuformix will receive a "significant upfront payment", additional development milestones and a royalty on net sales capped at £2mln a year. In return, Oxilio will get a licence to the patent estate and "know-how" related to NXP001.

[georgeo1] 22/3/2021 09:17

Looking good going forward.

[georgeo1] 22/3/2021 09:12

Still early days. More details to be released hopefully. Plans and moving ahead.

[jotoha2] 22/3/2021 09:08

Well that was a bit of a damp squid , lets see details of the deal , company certainly now has a proven product , bit surprised they have let it go so cheap , still must be tough to negotiate from a weak financial position , work with the majors , they have the funds .

[georgeo1] 22/3/2021 09:02

Might not go ahead with the placing now oxilio deal is done and still receive royalties.

[georgeo1] 22/3/2021 08:43

Just proposed.

[for fx sake] 22/3/2021 08:39

Those placees don't have their shares yet though, we've still got the EGM at the end of the month before that is confirmed.

[city analyst1] 22/3/2021 08:19

Positive news. However, and as my previous post indicates, it was pretty much a dead cert that Oxilio would exercise. To this end, and pardon my cynicism, but I believe today's news was timed to allow the 'City boys' (the 2p placees) to exit at 50% profit. And trust me, they will be offloading ('forward selling' their shares) today. So expect a lot of 'headfakes' (false spikes to lure PIs) throughout the day.

Also worth noting is that, Oxilio is a tiny company with very little money. It's yet to commence its March/April funding round. And until that is done, we don't know how much is likely to be coming our way.

That being said, today's news is still positive and marks completion of the first stage. Next stage is negotiations. This could take several weeks, if not months, before a deal is announced. So patience will be required in large amounts before we observe a genuine breakaway from this price range.

AIMHO.

[georgeo1] 22/3/2021 07:57

They did receive £500,000 from the initial £3 million. Which left £2.5 million anyway. Footers ran off with NFX design. Probably make copy if it.

[hollywood6] 22/3/2021 07:55

Have a read first

[for fx sake] 22/3/2021 07:53

Unlikely to happen. They said that in the previous RNS.

[georgeo1] 22/3/2021 07:48

Thanks couldn't find anywhere on newsummit. I thought they nfx are still awaiting to recover the £2.5million.

[georgeo1] 22/3/2021 07:46

Now only NXP002 and NXP004 to be licensed good days ahead.

[carlisle44] 22/3/2021 07:39

Is Oxillo exercising its option perchance? Posted Friday post 7380

Great news!

[for fx sake] 22/3/2021 07:21

Yes, multiple cancer targets too. You were right about the negotiations to come as well. I wonder how long it will now take to negotiate and if the undisclosed payment will remain undisclosed once it's agreed?I suppose even just several million will at least make up for the NSB default. There is also the fact that it further validates the technology and we are still free to pursue licensing for NXP001 as CINV treatment.Still a leaky ship though.

[jotoha2] 22/3/2021 07:14

Good news , 8p by end of day .

[soupdragon55] 22/3/2021 07:05

Good to see Oxilio exercise their option

[soupdragon55] 22/3/2021 06:58

Newsummit don't exist anymore and their director was charged with cooking the books.

[for fx sake] 21/3/2021 23:59

Newsummit don't pay their bills

[georgeo1] 21/3/2021 23:37

I was referring to newsummit.

[escapetohome] 21/3/2021 23:16

Interest building.

Nice.